Telehealth

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

Editorial Disclaimer: TotalCareMedical.com is an independent health and wellness research publication. This is not a medical practice. The platforms compared in this article are operating telehealth services that connect patients with licensed clinicians for compounded GLP-1 medication evaluation. Compounded GLP-1 medications are not FDA-approved finished drugs. Nothing in this article constitutes medical advice. Pricing referenced reflects each platform's published rates as of the review date.

The compounded-GLP-1 telehealth category has compressed pricing rapidly over the past eighteen months. Three platforms occupy the value end of the market that most patients evaluate: Oak Longevity, Mochi Health, and Hims. Each markets aggressively on price. Each presents the price differently. Patients comparing them on the marketing copy alone will not arrive at the right answer for their specific situation. This comparison takes the published pricing structures, normalizes them to total monthly out-of-pocket cost, and identifies which platform actually wins on cost — and where each platform fits clinically beyond the cost question.

Headline Pricing — What Each Platform Publishes

Oak Longevity publishes compounded semaglutide from $130 per month and compounded tirzepatide from $199 per month, with no separate membership fee, free shipping, and free health coaching included. The platform offers $50 off the first month with promotional code OAKNEW50.

Mochi Health publishes a $79 per month membership fee that includes provider visits, registered dietitian access, and care coordination, plus a separate $99 per month for compounded semaglutide or $199 per month for compounded tirzepatide at every dose. Total monthly out-of-pocket cost on Mochi semaglutide is therefore $178 per month, and Mochi tirzepatide is $278 per month.

Hims publishes compounded semaglutide injectable plans starting at $199 per month with a six-month prepayment commitment (approximately $1,194 upfront), and oral kit options starting at $69 per month with a ten-month prepayment commitment (approximately $690 upfront). The headline $69 per month figure refers to non-GLP-1 oral kit combinations rather than the GLP-1 active ingredient itself; the GLP-1 injectable pricing on Hims starts at $199 per month with prepay.

Total Monthly Cost — Normalized

Comparing on a single month, no prepayment, compounded semaglutide basis: Oak Longevity at $130 is the lowest. Mochi Health at $178 total is second. Hims at $199 with a six-month prepayment commitment is third by per-month figure but requires the most upfront capital.

Comparing on annualized cost at the published starting prices, semaglutide only: Oak at approximately $1,560 per year. Mochi at approximately $2,136 per year. Hims at approximately $2,388 per year on the six-month prepay structure. The difference between Oak and Mochi over a year — roughly $576 — is meaningful for patients on long-term GLP-1 therapy.

For tirzepatide, the gap narrows. Oak Longevity from $199 per month is approximately $2,388 per year. Mochi at $79 + $199 = $278 per month is approximately $3,336 per year. The Oak-to-Mochi annual gap on tirzepatide is approximately $948 — even larger in absolute dollars, though smaller as a percentage.

One critical caveat applies across all three platforms: these are starting or flat-rate published prices. Across the compounded-GLP-1 telehealth category, dose-specific pricing varies. Patients should confirm during the consultation whether the headline price applies at every titration step, particularly as patients move from initial low doses to clinically effective maintenance doses. This is a question worth asking on every platform, not just Oak. We covered the dose-titration consideration in detail in our Oak Longevity review.

Intake and Clinical Depth

Cost is one variable. Clinical fit is another. The three platforms differ meaningfully on how the clinical relationship is structured.

Oak Longevity uses an asynchronous intake — an online health questionnaire reviewed by a licensed provider, with no scheduled video visit required for initial evaluation. This is the fastest intake of the three and works well for patients with straightforward weight-management goals and no significant comorbid complexity. Patients can typically progress from intake to prescription approval within hours.

Mochi Health emphasizes live video visits with a board-certified obesity medicine physician or nurse practitioner, plus access to a registered dietitian for nutrition coaching. Mochi's care model is the most clinically intensive of the three. The cost — $79 per month membership for what would otherwise be billed as multiple separate visits and consultations — accounts for that depth. Patients with multiple comorbidities, complex weight histories, or those who want a registered dietitian's involvement will find Mochi's structure better suited even at the higher price.

Hims operates predominantly asynchronously, similar to Oak, but with structured follow-up check-ins built into the multi-month prepayment plan. The Hims clinical experience sits within a broader men's-health ecosystem rather than a dedicated obesity medicine specialty, though its providers are licensed clinicians who prescribe within state regulations. This topic connects to what we cover in ShedRX Review 2026: What to Confirm Before Paying.

Formulary Breadth

Patients who want only compounded semaglutide or compounded tirzepatide will find adequate access on all three platforms. The differences emerge when other options are needed.

Mochi Health offers the broadest formulary in the category, including FDA-approved brand-name medications when clinically appropriate (Wegovy, Ozempic, Mounjaro, Zepbound, Saxenda, Trulicity, Rybelsus), oral semaglutide tablets (the FDA-approved Rybelsus pathway), and non-GLP-1 alternatives (metformin, topiramate, naltrexone, bupropion, orlistat). Mochi also operates a pediatric-eligible weight-management program for patients under 18 with appropriate clinical criteria, which neither Oak nor Hims publishes.

Hims offers brand-name medications alongside compounded semaglutide and several oral kit combinations that include non-GLP-1 active ingredients. The Hims formulary is narrower than Mochi's but broader than Oak's.

Oak Longevity's formulary is compounded-focused, primarily compounded semaglutide and compounded tirzepatide. Patients seeking FDA-approved brand-name medications, oral GLP-1 tablets, or non-GLP-1 alternatives should confirm availability with Oak directly during the intake or evaluate a platform with broader documented options. For more on what compounded versus brand-name actually means for cost and outcomes, see our Compounded Semaglutide Cost analysis.

Brand-Name FDA-Approved Access

This is where the platforms diverge most sharply. Patients who specifically want — or whose clinical situation requires — an FDA-approved brand-name GLP-1 medication should plan accordingly.

Mochi Health and Hims both offer documented pathways to FDA-approved Wegovy, Ozempic, Mounjaro, and Zepbound when clinically appropriate. Brand-name medications cost substantially more out-of-pocket — typically several hundred to over a thousand dollars per month without insurance coverage — but represent the medications studied in the peer-reviewed STEP and SURMOUNT trials.

Oak Longevity's published platform is compounded-focused. The on-domain SynergyRx review covers a platform with broader brand-name access at higher prices. We covered SynergyRx's pricing structure for brand-name medications in our SynergyRx review, where Wegovy and Mounjaro start at approximately $947 per month and Ozempic starts at approximately $499 per month.

Cancellation and Commitment

Oak Longevity advertises “no subscriptions” and bills month-to-month based on the published platform information. Patients can stop ordering refills without committing to a fixed-duration contract. This flexibility has real value for patients uncertain whether GLP-1 therapy will fit their life long-term.

Mochi Health offers monthly billing as the default, plus 3-month and 12-month prepayment options that reduce the monthly figure by roughly $40. Cancellation is straightforward but requires actively cancelling both the membership and the medication subscription separately — a structure that has produced significant complaint volume in consumer review databases.

Hims requires multi-month prepayment commitments for the headline pricing tiers. The six-month prepay for injectable semaglutide and the ten-month prepay for oral kits both involve substantial upfront capital. Patients who change their mind during the prepayment period face refund navigation.

Who Each Platform Fits Best

Oak Longevity fits patients who want the lowest published starting price for compounded semaglutide on a no-membership-fee, no-prepayment basis, who are comfortable with asynchronous intake, and whose clinical situation is straightforward. The single-figure monthly price is the cleanest in the category.

Mochi Health fits patients who value live video provider access, registered dietitian involvement, broad formulary including brand-name and non-GLP-1 alternatives, and structured ongoing clinical care, and who can absorb the higher monthly total cost in exchange for that clinical depth.

Hims fits patients who can commit to multi-month prepayment, want access to both compounded and brand-name medications, and prefer the integration of weight management within a broader men's-health platform context.

The Honest Read

Oak Longevity wins the published-starting-price comparison on a no-commitment basis. That is real. It is also a starting price, and what any specific patient pays at maintenance dose depends on questions that must be answered during the consultation, not from a comparison table.

Mochi Health is more expensive monthly but delivers a more clinically intensive program with a broader formulary. For patients whose clinical situation benefits from that depth, the price differential is the right tradeoff. For patients with simpler situations, it is overpaying for unused capacity.

Hims is the highest barrier to entry due to prepayment requirements and is the most ecosystem-integrated platform of the three. Patients who already use Hims for other men's-health services may find the integration valuable; patients evaluating purely on weight-management terms will find better fit elsewhere.

For deeper coverage of the compounded GLP-1 telehealth category, see our Telehealth Platform Reviews hub. For evidence-based weight management beyond pharmaceutical interventions, see our Weight Management coverage. The clinical decision to use any GLP-1 medication, compounded or brand-name, belongs to the patient and a licensed healthcare provider.

Editorial Disclaimer: TotalCareMedical.com is an independent wellness research publication. It is not a medical practice and does not provide clinical care. All content is editorial and educational — not medical advice, diagnosis, or treatment. Compounded medications are prepared by licensed compounding pharmacies based on individual prescriptions and are not FDA-approved finished drugs. Pricing referenced reflects each platform's published rates as of the review date and is subject to change.

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

Important: Compounded tirzepatide discussed in this article is not FDA-approved and has not been evaluated by the FDA for safety or efficacy. This review is for educational purposes only. All prescribing decisions are made by licensed clinicians. Consult your healthcare provider before starting any prescription treatment. Tirzepatide is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Tirzepatide has generated more clinical trial interest than any other weight management medication in the last three years, and search volume for “tirzepatide telehealth” and “compounded tirzepatide” reflects that. MadeMed offers both injectable and oral compounded tirzepatide as part of its GLP-1 weight loss program. This article covers what tirzepatide actually is, what the clinical evidence base supports, how MadeMed's tirzepatide programs are structured and priced, the specific regulatory context around oral tirzepatide formats, and what to verify before enrolling.

What Tirzepatide Is and How It Differs from Semaglutide

Tirzepatide is a dual agonist — a single molecule that acts on two hormone receptor pathways simultaneously. It targets both GLP-1 (glucagon-like peptide-1) receptors and GIP (glucose-dependent insulinotropic polypeptide) receptors. Semaglutide, by contrast, acts on GLP-1 receptors only. This dual mechanism underlies tirzepatide's differentiated clinical profile.

GLP-1 receptor agonism suppresses appetite, slows gastric emptying, and supports blood glucose regulation — the same mechanism through which semaglutide works. GIP receptor agonism provides a complementary pathway that influences energy metabolism and may enhance GLP-1's effects on appetite and fat storage. In the SURMOUNT clinical trial program, once-weekly injectable tirzepatide at the 15mg dose produced average weight reduction of approximately 20 to 22 percent in adults with obesity — figures that exceeded the STEP trial results for injectable semaglutide at 2.4mg in comparable populations. These are the results from FDA-approved brand-name injectable tirzepatide (Zepbound) studied in peer-reviewed trials, not results established for compounded tirzepatide formulations.

Tirzepatide is FDA-approved as Mounjaro (for type 2 diabetes management) and Zepbound (for chronic weight management) — both as once-weekly subcutaneous injections. There is no FDA-approved oral tirzepatide product in any format as of the date of this review.

MadeMed Tirzepatide: Program Structure and Verified Pricing

MadeMed offers injectable and oral compounded tirzepatide through the same telehealth model as its semaglutide programs. Prospective patients complete an online medical intake reviewed by a licensed clinician affiliated with Xpedicare, LLC. Prescribing is at the clinician's sole discretion; no prescription is designed to deliver. If prescribed, medication is dispensed through AbsoluteRx and shipped directly to the patient.

Based on publicly available pricing verified through independent sources as of April 2026: injectable tirzepatide starts at $189 per month at the 2.5mg starting dose. This price includes L-Carnitine, physician consultation, overnight shipping, and injection supplies. MadeMed Club membership ($149/year) provides a $20 per month discount on tirzepatide programs — the largest per-month discount MadeMed offers across its programs — reflecting the higher base pricing of tirzepatide relative to semaglutide. At the $20/month discount rate, the Club membership pays for itself in approximately 7.5 months for patients on tirzepatide.

For oral tirzepatide: a confirmed starting price was not available in independently verified sources as of this writing. Verify the current pricing, availability, and dose tier structure for oral tirzepatide on mademed.com before enrolling. For context on how MadeMed's tirzepatide pricing compares to competitors: MEDVi lists injectable tirzepatide at $279 for the first month and $399 per month ongoing; the market range for compounded injectable tirzepatide across legitimate platforms runs approximately $189 to $699 per month, depending on platform, dose tier, and what is bundled into the monthly price. For a direct platform comparison, see our MadeMed vs. MEDVi comparison.

The Oral Tirzepatide Question: What Patients Need to Understand

This section is the most important part of this article for any patient considering oral tirzepatide, whether from MadeMed or any telehealth platform.

Tirzepatide is a large peptide molecule. As of the date of this review, Eli Lilly has not brought an FDA-approved oral tirzepatide product to market, and no oral tirzepatide formulation has completed phase 3 human clinical trials demonstrating bioavailability and efficacy through any oral delivery route. The reason is pharmacological: tirzepatide's molecular size and peptide structure make oral absorption exceptionally difficult without specialized delivery technology of the kind Novo Nordisk used in the development of oral semaglutide (Rybelsus/oral Wegovy), and even that technology required a decade of development and specific absorption-enhancing excipients.

What telehealth platforms offering “oral tirzepatide” provide is a compounded sublingual formulation—a tablet or lozenge that dissolves under the tongue, relying on sublingual mucosal absorption rather than gastrointestinal absorption. The theoretical mechanism is sound in principle. But there is no published phase 3 human trial data establishing that compounded sublingual tirzepatide achieves meaningful systemic exposure or produces clinical outcomes comparable to injectable tirzepatide. This is a more significant evidence gap than that for compounded oral semaglutide, because oral semaglutide at least has FDA-approved reference products with established human bioavailability data. No equivalent reference product exists for oral tirzepatide.

This is not a reason to dismiss the format categorically. Clinicians prescribe compounded formulations for reasons that are specific to individual patients, and the prescribing decision belongs to the licensed provider who has reviewed your health history. But patients deserve to understand that “oral tirzepatide” through a telehealth platform is a compounded sublingual formulation without an established human efficacy evidence base, not a pill equivalent of Zepbound.

Tirzepatide vs. Semaglutide: Which Is Right for You?

This is a clinical question, not a content question — and it deserves to be answered by a licensed provider who knows your health history. What we can offer is the factual framework. Tirzepatide's dual mechanism has been associated with greater average weight reduction in clinical trials directly comparing the two agents. That does not mean tirzepatide is better for every individual patient. Semaglutide has a longer safety track record, a larger published evidence base, and lower published starting prices at MadeMed and most other platforms. Individual response to GLP-1 and GIP receptor agonism varies. Some patients respond better to one mechanism than the other. The only way to know is a clinical evaluation followed by a structured trial with appropriate monitoring.

For patients who have already tried semaglutide and not achieved an adequate response, tirzepatide represents a mechanistically distinct alternative worth discussing with a prescribing clinician. For patients new to GLP-1 therapy without a prior treatment history, either agent may be appropriate — the decision belongs to the clinician reviewing your specific case. For our full breakdown of MadeMed's complete program offering across both semaglutide and tirzepatide, see our MadeMed platform review. For the oral format evidence comparison across both molecules, see our oral vs. injectable GLP-1 comparison.

Frequently Asked Questions

How does tirzepatide differ from semaglutide?

Semaglutide is a GLP-1 receptor agonist — it mimics one hormone involved in appetite regulation and blood glucose control. Tirzepatide is a dual agonist that acts on both GLP-1 and GIP receptors. The dual mechanism has been associated with greater average weight reduction in clinical trials comparing the two agents, though individual response varies and both require physician evaluation and ongoing medical supervision.

Is MadeMed's oral tirzepatide FDA-approved?

No. As of the date of this review, no oral tirzepatide product has received FDA approval in any format. The oral tirzepatide available through MadeMed and other telehealth platforms is a compounded sublingual formulation. It is not FDA-approved, has not been evaluated by the FDA for safety or efficacy, and should not be interpreted as equivalent to any FDA-approved injectable tirzepatide product.

How much does MadeMed tirzepatide cost?

Based on published April 2026 pricing, MadeMed lists injectable tirzepatide starting at $189 per month at the 2.5mg starting dose, including L-Carnitine, physician consultation, overnight shipping, and injection supplies. MadeMed Club membership ($149/year) provides a $20 per month discount. Oral tirzepatide starting price was not confirmed in independently verified sources as of this writing — verify current pricing directly on mademed.com before enrolling.

What are the most common side effects of tirzepatide?

The most commonly reported side effects in clinical trial data include nausea, diarrhea, vomiting, and constipation. These are dose-dependent and typically most pronounced during dose escalation, often improving after several weeks at a stable dose. Serious contraindications include personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. A licensed prescribing clinician should review your full medical history before tirzepatide is prescribed.

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

Important: Both MadeMed and MEDVi facilitate access to compounded prescription medications that are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This comparison is for educational purposes only. Consult a licensed healthcare provider before starting any prescription treatment. Pricing is subject to change — verify current terms directly on each platform's official website before enrolling.

If you've been researching compounded GLP-1 telehealth programs, you've almost certainly encountered both MadeMed and MEDVi. They're two of the more visible platforms in the current market, they offer overlapping medication formats, and they're both frequently appearing in the same search results. What they don't offer is a side-by-side comparison written by someone who has actually read both platforms' terms, sourced verified pricing, and documented the meaningful differences. That's what this article does.

Company Overview: What Each Platform Is

MadeMed is operated by IDL Health LLC, headquartered in Houston, Texas. Medical services are provided by Xpedicare, LLC, an independent medical group whose licensed clinicians make all prescribing decisions. Medication is dispensed through AbsoluteRx, MadeMed's licensed pharmacy partner. MadeMed holds LegitScript certification. As of available verified sources, no FDA warning letters have been identified for MadeMed as of the date of this review.

MEDVi is a telehealth platform that has been operating since 2023 and is based in Newark, Delaware. Prescriptions are overseen by board-certified U.S. physicians through the OpenLoop Health provider network. Medication is dispensed through Belmar Pharma Solutions, a licensed compounding pharmacy operating since 1985 and accredited by NABP across all its locations. MEDVi holds LegitScript certification and reports serving over 100,000 patients. MEDVi received an FDA warning letter in February 2026, citing misbranding violations — specifically, marketing language the FDA found implied FDA approval and suggested MEDVi was the compounder of the medications it sold. The letter did not allege contaminated or improperly manufactured medications. For our full independent review of MEDVi's platform, see our MEDVi GLP-1 program review.

Verified Pricing Comparison: What Each Platform Actually Charges

The pricing figures below are drawn from publicly available sources verified as of April to May 2026. All prices represent published starting doses. Dose increases typically increase cost. Verify current pricing directly on each platform before enrolling.

Injectable Semaglutide: MadeMed lists $179 per month at the starting dose (0.25mg), inclusive of L-Carnitine, physician consultation, overnight shipping, and injection supplies. MadeMed Club membership ($149/year) reduces this by $10 per month. MEDVi lists $179 for the first month as an introductory rate, then $299 per month for ongoing refills. MEDVi charges no separate membership fee.

Oral Semaglutide (sublingual): MadeMed lists $169 per month at the starting dose (1mg), with 30 sublingual tablets. MadeMed Club reduces this by $10 per month. MEDVi lists oral semaglutide tablets starting at $249 for the first month, then $369 per month ongoing. At every dose tier in available verified data, MadeMed's published oral semaglutide price is lower than MEDVi's.

Injectable Tirzepatide: MadeMed lists $189 per month at the starting dose (2.5mg), inclusive of the same supplies package as semaglutide. MadeMed Club reduces this by $20 per month. MEDVi lists injectable tirzepatide starting at $279 for the first month, then $399 per month ongoing.

Oral Tirzepatide (sublingual): Neither platform has a confirmed published starting price for oral tirzepatide in independently verified sources as of this writing. MEDVi's ongoing rate for compounded tirzepatide (injectable and oral combined into one tier) is reported at $399 per month. Verify oral tirzepatide pricing and current availability directly on each platform. Note: as of January 2026, there is no FDA-approved oral tirzepatide product in any format. Oral tirzepatide from telehealth platforms is a compounded sublingual formulation that has not been evaluated by the FDA.

One structural pricing difference worth understanding: MEDVi bills on a 28-day cycle rather than a calendar month, producing 13 billing events per year rather than 12. At $299 per month for semaglutide, the annual cost is approximately $3,887 — not $3,588 as a 12-month calculation would suggest. MadeMed's billing cycle structure (30-day vs. 90-day subscription options) should be verified directly on the platform.

What's Included: The Bundling Difference

MadeMed explicitly states that its injectable programs include L-Carnitine, physician consultation, overnight shipping, and injection supplies in the listed monthly price. For patients who would otherwise pay separately for these items, the all-in pricing model simplifies cost comparison. MEDVi's pricing includes provider consultation and medication; verify current shipping and supply terms directly on MEDVi's platform, as bundling structures in the telehealth market can change.

The MadeMed Club membership ($149/year) provides monthly discounts of $10 on semaglutide programs and $20 on tirzepatide programs. At the tirzepatide discount rate, the membership pays for itself in approximately 7.5 months. For patients planning a sustained treatment course, the math favors joining. For patients uncertain about long-term commitment, the month-to-month standard pricing avoids the upfront membership cost.

Medication Range: Where the Platforms Diverge

For GLP-1 programs specifically, both platforms offer the same four core formats: injectable semaglutide, oral sublingual semaglutide, injectable tirzepatide, and oral sublingual tirzepatide. MEDVi additionally offers access to brand-name Wegovy and Ozempic at premium pricing tiers for patients who specifically require FDA-approved finished drug products — an option MadeMed does not appear to offer, according to available verified sources.

MadeMed's range extends beyond GLP-1 into categories MEDVi doesn't cover: sermorelin-based peptide therapy in injectable and oral formats, a tadalafil/Apomorphine/oxytocin men's wellness troche, and NAD+ therapy in injectable and nasal spray formats. For patients whose clinical needs include any of these categories, in addition to weight management, MadeMed offers a single-platform model that MEDVi doesn't match. For our detailed breakdown of MadeMed's peptide and NAD+ programs, see our MadeMed sermorelin and peptide therapy review.

Regulatory History: What the Record Shows

This section matters more in 2026 than it would have in prior years, given the FDA's escalated enforcement posture in the compounded GLP-1 market since September 2025.

MEDVi received a formal FDA warning letter in February 2026. The letter cited misbranding violations specifically — marketing language the agency found implied FDA approval and mischaracterized MEDVi as the compounder of the medications it sold. MEDVi holds active LegitScript certification as of the publication date of this review, and the warning letter did not allege medication contamination or manufacturing deficiencies. Warning letters require a response and corrective action; they do not automatically result in enforcement action or platform shutdown. But they are on the public record, and patients evaluating platforms should know they exist.

No FDA warning letters have been identified for MadeMed in available verified sources as of this writing. This is not a commitment of future regulatory status — the compounded GLP-1 market remains under active FDA scrutiny, and conditions for all platforms in this space continue to evolve.

Patient Review Volume and Signals

MEDVi has a substantially larger public review footprint: over 10,000 Trustpilot reviews with a 4.4 to 4.5 star average as of early 2026. Common praise focuses on fast approval, clinical team responsiveness, and accessible provider messaging. Common complaints cluster around billing practices and subscription management — a pattern typical of telehealth platforms using auto-renewal subscription models, not a signal specific to clinical quality.

MadeMed has a smaller public review volume, consistent with its relative market age. A smaller review footprint does not indicate lower quality — it reflects how recently a platform entered the market and how aggressively it has solicited public reviews. Evaluate review signals as one data point among several, not as a primary decision factor.

State Availability

MEDVi reports availability in 49 states (North Dakota excluded as of early 2026 data). MadeMed reports availability in approximately 40 states. If your state's availability is a deciding factor, verify both platforms' current service areas directly — state-level availability in the telehealth GLP-1 market changes as platforms adjust to evolving state telehealth regulations.

How to Choose Between Them

If your primary goal is compounded GLP-1 for weight management and you want the lowest published starting price across semaglutide formats, MadeMed's published pricing is lower at every tier in the verified data. If you want access to brand-name FDA-approved GLP-1 options through the same platform, MEDVi offers that and MadeMed does not appear to. If you need peptide therapy or NAD+ alongside a GLP-1 program, MadeMed is the single-platform option. If you want the largest available patient review base as a signal before committing, MEDVi's review volume is substantially larger. If FDA warning letter history factors into your evaluation, MEDVi has one on record from February 2026 and MadeMed does not.

Neither of these is a definitive answer about which platform is better for any individual patient. The right platform is the one whose clinical team, after reviewing your specific health history, determines an appropriate treatment path for you. Both platforms use licensed clinicians for that determination. Both use licensed pharmacy partners for dispensing. Both operate under the same compounded medication regulatory framework. The differences are in pricing structure, medication range, regulatory history, and review volume — all of which are factors you can evaluate before completing an intake form. For our full breakdowns, see the complete MadeMed review and the complete MEDVi review.

Frequently Asked Questions

Is MadeMed or MEDVi cheaper for injectable semaglutide?

Based on published April 2026 pricing, MadeMed lists injectable semaglutide at $179 per month — identical to MEDVi's introductory first-month rate. MEDVi's ongoing monthly rate after the first month rises to $299. MadeMed's published pricing does not clearly distinguish between an introductory and an ongoing rate in the available verified sources; verify current tier pricing directly on each platform before enrolling.

Did MEDVi receive an FDA warning letter?

Yes. MEDVi received an FDA warning letter in February 2026, citing misbranding violations — specifically, marketing language that implied FDA approval and mischaracterized MEDVi as the compounder of the medications it sold. The letter did not allege that the medications were contaminated or improperly manufactured. MEDVi holds an active LegitScript certification as of the publication date of this review.

Which platform offers more medication formats?

Both platforms offer compounded semaglutide and tirzepatide in injectable and sublingual oral formats. MadeMed additionally offers sermorelin peptide therapy (injectable and oral) and NAD+ therapy (injectable and nasal spray). MEDVi offers brand-name Wegovy and Ozempic at premium pricing tiers. The right platform depends on which medications and categories are relevant to your individual situation.

Which platform has more patient reviews?

MEDVi has a substantially larger public review footprint, with over 10,000 Trustpilot reviews and an average rating of 4.4 to 4.5 as of early 2026. MEDVi has been operating since 2023 and reports serving over 100,000 patients. MadeMed has a smaller public review volume reflecting its relative market age. Review volume and scores are useful signals, but should not be the sole basis for a prescribing decision.

Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.

Important: Sermorelin and other peptide therapies discussed in this article are prescription medications. Compounded formulations are not FDA-approved and have not been evaluated by the FDA for safety or efficacy. This content is for educational purposes only. Consult your licensed healthcare provider before starting any prescription peptide therapy.

Most coverage of MadeMed focuses on its GLP-1 weight-loss programs, which makes sense — that's where patient volume and search interest are highest. But MadeMed also offers sermorelin-based peptide therapy in both injectable and oral formats, and that category deserves the same research-depth treatment this site applies to every telehealth program we review. This article covers what sermorelin is, what the clinical evidence actually supports, how MadeMed's peptide programs are structured, and the regulatory context you need to understand before enrolling.

What Is Sermorelin?

Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone, or GHRH. Rather than introducing exogenous growth hormone directly — as growth hormone replacement therapy does — sermorelin stimulates the pituitary gland to produce and release growth hormone via the body's natural regulatory feedback mechanisms. This distinction matters clinically. Because sermorelin operates upstream of growth hormone production rather than bypassing the regulatory system entirely, it preserves the pituitary's own feedback controls to a greater degree than direct growth hormone administration.

Sermorelin was previously FDA-approved under the name Geref for the evaluation and treatment of growth hormone deficiency in children. That approval was voluntarily withdrawn by the manufacturer — not due to a safety finding, but for commercial reasons. Sermorelin prescribed through telehealth platforms today is compounded, meaning it is formulated by a licensed compounding pharmacy for specific patients and is not an FDA-approved finished drug product.

What the Research Supports — and What It Doesn't

The evidence base for sermorelin is meaningful but narrower than its marketing footprint might suggest. Published research has examined sermorelin's effects on growth hormone secretion, IGF-1 levels, body composition, and sleep quality in specific populations, primarily adults with documented growth hormone deficiency or age-related growth hormone decline. Studies have shown that sermorelin can stimulate measurable increases in growth hormone output in appropriate patient populations when administered via injection. The clinical rationale for its use exists.

What the research does not support: sermorelin as a general anti-aging treatment, as a performance enhancement tool for individuals with normal growth hormone levels, or as a designed to deliver approach to improving body composition or energy in non-deficient adults. Sermorelin is not approved for these applications. No legitimate medical provider can designed to support outcomes from peptide therapy, and claims that sermorelin will produce specific effects on body composition, energy, or longevity in unselected patient populations exceed what peer-reviewed evidence supports.

The more difficult research question applies specifically to oral sermorelin. Peptides face significant challenges with oral bioavailability. The gastrointestinal tract contains proteases that degrade peptides before they reach systemic circulation, which is why most established peptide therapies use injectable delivery routes. The clinical evidence base for oral sermorelin formulations — including any sublingual or swallowed tablet format — is substantially more limited than for injectable sermorelin. This is not unique to MadeMed; it applies to oral peptide delivery across the telehealth market.

How MadeMed's Peptide Therapy Programs Are Structured

MadeMed offers sermorelin in both injectable and oral formats. The enrollment process follows the same telehealth model as the platform's GLP-1 programs: prospective patients complete an online medical intake, which is reviewed by a licensed clinician affiliated with Xpedicare, LLC. Prescribing is at the clinician's sole discretion. There is no commitment that a prescription will be issued. Medication is dispensed through AbsoluteRx, MadeMed's licensed pharmacy partner, and shipped directly to the patient.

Sermorelin is typically administered at night, before sleep, because growth hormone secretion follows a circadian pattern with peak release during slow-wave sleep. Injectable sermorelin is administered subcutaneously — the same delivery method as injectable GLP-1 medications. Dosing and titration protocols are determined by the prescribing clinician based on individual patient assessment.

The subscription and billing structure for peptide therapy follows the same terms as MadeMed's other programs: recurring billing (30 or 90 day cycles), no prorated refunds, cancellation available via email or through the patient portal. Review the full Terms of Use at mademed.com before enrolling.

NAD+ Therapy: MadeMed's Other Longevity Category

MadeMed also offers NAD+ (nicotinamide adenine dinucleotide) therapy in injectable and nasal spray formats, priced up to $269 per month for the nasal spray at higher tiers. NAD+ is a coenzyme involved in cellular energy metabolism, and there is ongoing research interest in NAD+ precursors and direct NAD+ supplementation in the context of aging and metabolic health. As with sermorelin, the clinical evidence base for NAD+ therapy in healthy, non-deficient adults — and specifically for injectable and nasal spray formats at the doses used in telehealth programs — is substantially more limited than the marketing language around “longevity medicine” typically conveys. Discuss the evidence with your provider before starting any NAD+ program.

Who Peptide Therapy May Be Appropriate For

Sermorelin may be clinically appropriate for adults with documented growth hormone deficiency confirmed through lab testing, or for individuals where a licensed clinician determines it may be medically indicated after reviewing individual health history and goals. It is not a general wellness product and is not appropriate as a self-directed supplement or as a substitute for lifestyle interventions in growth-hormone-sufficient adults. Clinical evaluation before prescribing — including a thorough health history review — is the baseline standard for any responsible peptide therapy program.

If you're researching MadeMed primarily for weight loss support, the GLP-1 programs are the more evidence-anchored starting point. See our full MadeMed platform review for a complete breakdown of all programs, pricing, and what to verify before enrolling. For comparison with other telehealth platforms that offer peptide therapy alongside GLP-1 programs, see our review of TeleHealth Med, which covers a comparable care model.

What to Ask Your Provider Before Starting Sermorelin

Has your growth hormone status been evaluated through lab testing? What IGF-1 levels would indicate you're a candidate for sermorelin therapy? Will you receive a baseline lab assessment before prescribing? What does dose titration look like and how is response monitored over time? What is the compounding pharmacy's accreditation status and quality assurance process for the specific formulation? How long is a reasonable trial period before evaluating whether the therapy is producing any measurable response? Are there contraindications given your current medications or health history?

These are not difficult questions — they're the baseline clinical due diligence any responsible provider should be prepared to answer. A platform or provider that can't or won't engage with them is a signal to seek a different clinical relationship.

Frequently Asked Questions

What is sermorelin and how does it work?

Sermorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). It works by stimulating the pituitary gland to produce and release growth hormone through the body's natural regulatory pathways, rather than introducing exogenous growth hormone directly. It requires a licensed provider evaluation and is not approved for anti-aging or general wellness use. Clinical applications have included evaluation for growth hormone deficiency under physician supervision.

Is MadeMed's sermorelin FDA-approved?

Sermorelin was previously FDA-approved as Geref for pediatric growth hormone deficiency, but that approval was voluntarily withdrawn by the manufacturer. Sermorelin prescribed through telehealth platforms today is typically compounded, meaning it is not an FDA-approved finished drug product and has not been evaluated by the FDA for safety or efficacy in its compounded form.

What is the difference between injectable and oral sermorelin at MadeMed?

MadeMed offers both injectable and oral sermorelin formats. Injectable sermorelin is administered subcutaneously and is the more established delivery route in clinical literature. Oral peptide delivery faces significant bioavailability challenges due to degradation in the gastrointestinal tract. The clinical evidence base for oral sermorelin formulations is substantially more limited than for injectable formats. Discuss which format is appropriate for your situation with a licensed provider before starting.